CDKN2A and carcinoma: Finally, late recurrences were rare in OPSCC, and patients with p16+ TSCC/BOTSCC did not have a higher frequency of late metastasis compared to those with corresponding p16− carcinomas, nor did p16+ status in their carcinomas affect outcome after recurrence.